- Home
- SFWL vs ATYR Comparison
SFWL vs ATYR Comparison
Compare SFWL & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFWL | ATYR |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | China | United States |
| Employees | N/A | 58 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.6M | 73.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | SFWL | ATYR |
|---|---|---|
| Price | $0.98 | $0.82 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 6.0K | ★ 972.3K |
| Earning Date | 03-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.64 |
| 52 Week High | $1.29 | $7.29 |
Technical Indicators
Market Signals| Indicator | SFWL | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 55.97 | 48.87 |
| Support Level | $0.92 | $0.82 |
| Resistance Level | $1.00 | $0.86 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 50.06 | 66.87 |
Price Performance
Historical ComparisonAbout SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).